Jane Hirsh
Ms. Hirsh was Founder, President, and CEO of Copley Pharmaceutical, Inc., a large, successful generic pharmaceutical company. During her tenure, the Company completed over 80 ANDAs and attained revenues of $160 million prior to its acquisition. In 1993, Hoechst Celanese Corporation, the chemical and drug concern, acquired 51 percent of Copley Pharmaceutical Inc. for $546 million. In 2000, Copley was sold to Teva Pharmaceuticals. Jane is a co-inventor on over 9 patent applications and has over 40 years of experience in the pharmaceutical and related healthcare industries. In 2003, Ms. Hirsh co-founded and served as Chairman of Collegium Pharmaceutical. As a specialty pharmaceutical company, Collegium focused on intellectual property development under jane’s leadership. Onset Therapeutics, a dermatological specialty company, was founded in 2007 as a subsidiary of Collegium and sold to Precision Dermatology in 2010. In addition, Jane has served on the Board of Trustees for Tufts University and the Museum of Science, Boston.